SCHEMBL23210951

SCHEMBL23210951

COc1ccc(Cn2nc(-c3ccc(C4CCC(NC(=O)O)C4)nc3)c3nc(-c4cccc5c4CCC5)c(OC)cc32)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GYS1 P13807 1/20 0.35
MAPT P10636 4/20 0.34
PTGIR P43119 2/20 0.34
BUB1 O43683 2/20 0.34
PTGDR Q13258 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
KMT2A Q03164 1/20 0.33
JAK2 O60674 1/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PPARG P37231 2/20 0.33
AOC3 Q16853 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29907045 0.92 BUB1 (0.34) GYS1MAPTPTGIRBUB1PTGDR
SCHEMBL23210807 0.92 BUB1 (0.34) GYS1MAPTPTGIRBUB1PTGDR
SCHEMBL29907037 0.92 RET (0.34) GYS1MAPTPTGIRBUB1PTGDR
SCHEMBL23264016 0.92 RET (0.34) GYS1MAPTPTGIRBUB1PTGDR
SCHEMBL23211061 0.89 GYS1 (0.35) GYS1PTGIRBUB1PTGDRPDE4A
SCHEMBL29907104 0.89 BUB1 (0.35) MAPTPTGIRBUB1PTGDRPDE4A
SCHEMBL23210989 0.89 BUB1 (0.35) MAPTPTGIRBUB1PTGDRPDE4A
SCHEMBL23211007 0.88 PDE4A (0.36) GYS1PTGIRBUB1PTGDRPDE4A
SCHEMBL23211062 0.88 BUB1 (0.34) GYS1MAPTPTGIRBUB1PTGDR
SCHEMBL29008815 0.88 PDE4A (0.34) GYS1MAPTPTGIRBUB1PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GYS1 4157/4885MAPT 4204/4885PTGIR 2460/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 GYS1 4157/4885MAPT 4204/4885PTGIR 2460/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GYS1 4157/4885MAPT 4204/4885PTGIR 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.